Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreement (Details)

v3.21.2
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Dec. 31, 2020
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues       $ 14,667   $ 29 $ 22,201 $ 88
License Agreement Terms | Otuska                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront payments received   $ 50,000         $ 0  
Potential regulatory milestone revenue   $ 50,000            
Revenues     $ 50,000   $ 50,000      
License Agreement Terms | Otuska | Minimum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   10.00%            
License Agreement Terms | Otuska | Maximum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   20.00%            
License Agreement Terms | Riptide Bioscience, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront license fee $ 6,000